AVISE® Testing Revenue Drives 27% Revenue Growth SAN DIEGO , Nov. 12, 2019 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis

SAN DIEGO , Nov. 07, 2019 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention, today

SAN DIEGO , Oct. 29, 2019 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention, today

SAN DIEGO , Oct. 28, 2019 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention, today

SAN DIEGO , Oct. 24, 2019 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), is pleased to announce clinical study support for Horizon Therapeutics plc (Nasdaq: HZNP) to measure methotrexate polyglutamates (MTXPGs), the active metabolites of methotrexate (MTX) in the MIRROR Randomized Controlled Trial

CEO Ron Rocca Will Be Recognized at LFA Annual Evening of Hope Gala in New York City SAN DIEGO , Oct. 21, 2019 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by

First ever prospective randomized multicenter clinical utility study shows the favorable impact of AVISE® Lupus on clinical decision-making and patient management SAN DIEGO , Oct. 15, 2019 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum

SAN DIEGO, Calif., Sept. 23, 2019 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN),  an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention,

San Diego, CA, Sept. 18, 2019 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN),  an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention,

San Diego, CA and Albuquerque, NM, Aug. 19, 2019 (GLOBE NEWSWIRE) -- Exagen Inc., an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention,